Open-Label Extension of Other SZ1839 (Iressa) Trials

Phase 3

Completed

• Conditions: Cancer

• Registration Number: NCT00635973
• Lead Sponsor: AstraZeneca

Brief Summary

A trial to assess patients who have been treated with Iressa in a previous clinical trial and may benefit from continued treatment with Iressa.

Detailed Description

Not available

Study Timeline

• Study Start: 2000-02
• Study Completion: 2003-10
• Study First Submitted: 2008-03-07
• Study First Submitted QC: 2008-03-13
• Study First Posted: 2008-03-14
• Status Verified: 2009-04
• Last Update Submitted: 2009-04-21
• Last Update Posted: 2009-04-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• Received treatment in a previous Iressa clinical trial
• Provided Informed Consent to participate in the trial
• 30 days or less since completing the previous Iressa trial.

Exclusion Criteria

• Radiotherapy completed more than 14 days before starting treatment in this trial
• Incomplete healing from prior surgery
• Withdrawal from previous Iressa trial due to unacceptable toxicity to major organs

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Adverse Events	Every 28 days

Secondary Outcome Measures

Name	Time	Method
Progression Free Survival	Every 28 days
Survival	Every 28 days